Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Autoimmunity Reviews
|
April 22, 2022
Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders
Marina Mané-Damas, Peter C Molenaar, Peter Ulrichts, et al.
European Journal of Neurology
|
October 16, 2023
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study
Vera Bril, James F Howard, Chafic Karam, et al.
Journal of Immunotoxicology
|
February 13, 2025
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys
Ornella Binazon, Mario Cocco, Daniel Thwaites, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 4, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod
Fatemeh Khani-Habibabadi, Fien M Verhamme, Mahan Moshir, et al.
Mabs
|
February 5, 2014
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Karen Silence, Torsten Dreier, Mahan Moshir, et al.
Human Vaccines & Immunotherapeutics
|
March 3, 2025
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models
Prajakta Warang, Gagandeep Singh, Mahan Moshir, et al.
Experimental Neurology
|
March 10, 2019
Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis
Maartje G Huijbers, Jaap J Plomp, Inge E van Es, et al.
The Lancet. Neurology
|
June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
James F Howard, Vera Bril, Tuan Vu, et al.
JCI Insight
|
May 7, 2024
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Guanglong Ma, Andrew R Crowley, Liesbeth Heyndrickx, et al.
Nature Communications
|
October 14, 2022
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
Maximilian Brinkhaus, Erwin Pannecoucke, Elvera J van der Kooi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Autoimmunity Reviews
|
April 22, 2022
Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders
Marina Mané-Damas, Peter C Molenaar, Peter Ulrichts, et al.
European Journal of Neurology
|
October 16, 2023
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study
Vera Bril, James F Howard, Chafic Karam, et al.
Journal of Immunotoxicology
|
February 13, 2025
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys
Ornella Binazon, Mario Cocco, Daniel Thwaites, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 4, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod
Fatemeh Khani-Habibabadi, Fien M Verhamme, Mahan Moshir, et al.
Mabs
|
February 5, 2014
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Karen Silence, Torsten Dreier, Mahan Moshir, et al.
Human Vaccines & Immunotherapeutics
|
March 3, 2025
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models
Prajakta Warang, Gagandeep Singh, Mahan Moshir, et al.
Experimental Neurology
|
March 10, 2019
Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis
Maartje G Huijbers, Jaap J Plomp, Inge E van Es, et al.
The Lancet. Neurology
|
June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
James F Howard, Vera Bril, Tuan Vu, et al.
JCI Insight
|
May 7, 2024
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Guanglong Ma, Andrew R Crowley, Liesbeth Heyndrickx, et al.
Nature Communications
|
October 14, 2022
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
Maximilian Brinkhaus, Erwin Pannecoucke, Elvera J van der Kooi, et al.
Page
of 3